Literature DB >> 21487326

The tuberculin skin test is unreliable in school children BCG-vaccinated in infancy and at low risk of tuberculosis infection.

Sandy Jacobs1, Andrea Warman, Ruth Richardson, Wadieh Yacoub, Angela Lau, Denise Whittaker, Sandy Cockburn, Geetu Verma, Jody Boffa, Gregory Tyrrell, Dennis Kunimoto, Jure Manfreda, Deanne Langlois-Klassen, Richard Long.   

Abstract

BACKGROUND: The tuberculin skin test (TST) is often used to screen for latent tuberculosis infection (LTBI) in school children, many of whom were bacille Calmette-Guérin (BCG)-vaccinated in infancy. The reliability of the TST in such children is unknown.
METHODS: TSTs performed in low-risk BCG-vaccinated and -nonvaccinated grade 1 and grade 6 First Nations (North American Indian) school children in the province of Alberta, Canada, were evaluated retrospectively. To further assess the specificity of the TST, BCG-vaccinated children with a positive TST (≥10 mm of induration) and no treatment of LTBI were administered a QuantiFERON-TB Gold In-Tube test (QFT-GIT, Cellestis International).
RESULTS: A total of 3996 children, 2063 (51.6%) BCG-vaccinated and 1933 (48.4%) BCG-nonvaccinated, were screened for LTBI. Vaccinated children were more likely than nonvaccinated children to be TST positive (5.7% vs. 0.2%, P < 0.001). Vaccinated children with a positive TST were more likely to have a recent past TST as compared with those with a negative TST (6.8% versus 2.8%, P = 0.01). Among 65 BCG-vaccinated TST-positive children who underwent a QFT-GIT, only 5 (7.7%; 95% CI: 2.5%, 17.0%) were QFT-GIT positive. A TST of ≥15 mm was more likely to be associated with a positive QFT-GIT than a TST of 10 to 14 mm, 16.0% (95% CI: 4.5%, 36.1%) versus 2.5% (95% CI: 0.1%, 13.2%), P = 0.047.
CONCLUSION: The TST is unreliable in school children, BCG-vaccinated in infancy, and who are at low risk of infection. The QFT-GIT is a useful confirmatory test for LTBI in BCG-vaccinated TST-positive school children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487326     DOI: 10.1097/INF.0b013e31821b8f54

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening.

Authors:  Akiko Kowada
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

2.  Potential role for interferon-γ release assays in tuberculosis screening in a remote Canadian community: a case series.

Authors:  Wilson Kwong; Thomas Krahn; Ann Cleland; Janet Gordon; Wendy Wobeser
Journal:  CMAJ Open       Date:  2016-09-22

Review 3.  Recommendations for pediatric tuberculosis vaccination in Italy.

Authors:  Carlotta Montagnani; Susanna Esposito; Luisa Galli; Elena Chiappini; Nicola Principi; Maurizio de Martino
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

4.  The feasibility of the interferon gamma release assay and predictors of discordance with the tuberculin skin test for the diagnosis of latent tuberculosis infection in a remote Aboriginal community.

Authors:  Gonzalo G Alvarez; Deborah D Van Dyk; Naomi Davies; Shawn D Aaron; D William Cameron; Marc Desjardins; Ranjeeta Mallick; Natan Obed; Maureen Baikie
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

5.  Tuberculosis screening by tuberculosis skin test or QuantiFERON-TB Gold In-Tube Assay among an immigrant population with a high prevalence of tuberculosis and BCG vaccination.

Authors:  John A Painter; Edward A Graviss; Hoang Hoa Hai; Duong Thi Cam Nhung; Tran Thi Thanh Nga; Ngan P Ha; Kirsten Wall; Le Thien Huong Loan; Matt Parker; Lilia Manangan; Rick O'Brien; Susan A Maloney; R M Hoekstra; Randall Reves
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

6.  Relation between BCG vaccine scar and an interferon-gamma release assay in immigrant children with "positive" tuberculin skin test (≥10 mm).

Authors:  Margret Johansson Gudjónsdóttir; Karsten Kötz; Ruth Stangebye Nielsen; Philip Wilmar; Sofia Olausson; Daniel Wallmyr; Birger Trollfors
Journal:  BMC Infect Dis       Date:  2016-10-06       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.